Asthma

Asthma · R&I · 7 drugs · 8 indications

Chronic airway inflammation with bronchospasm.

Competitive Landscape (7 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
Vamikibart	ROG.SW	Anti-IL-13	Antibody	SC	PHASE3
tozorakimab	AZN	IL-33 inhibitor	Antibody	SC	PHASE3
Tezspire	AMGN, AZN	TSLP inhibitor	Antibody	SC	APPROVED
Xolair	ROG.SW, NVS	IgE antagonist	Antibody	SC	APPROVED
Airsupra	AZN	ICS/SABA combination	Inhaler	INHALATION	APPROVED
Fasenra	AZN	IL-5 receptor antagonist	Antibody	SC	APPROVED
Dupixent	REGN	IL-4Rα inhibitor (monoclonal antibody)	Monoclonal antibody	SC	APPROVED

Indications (8)

Allergic asthma

Xolair APPROVED

Moderate-to-severe asthma (<6 years)

Severe Asthma

Moderate-to-severe asthma (≥12 years, eosinophilic/OCS-dependent)

Dupixent APPROVED

Moderate-to-severe asthma (6-11 years)

Dupixent APPROVED

Asthma

Severe eosinophilic asthma

Fasenra APPROVED

Asthma (as-needed)

Airsupra APPROVED

Upcoming Catalysts

Tozorakimab - COPD - Ph3 - Topline (OBERON)CLINICAL

AZNH1 2026

Dupixent - CSU - Ph3 Topline (LIBERTY-CSU CUPID)CLINICAL

REGN2026

Tezspire - EoE - Ph3 - ToplineCLINICAL

AZNH2 2026

Xolair - Biosimilar CompetitionCOMPETITIVE

ROG.SWH2 2026

Tezspire - COPD - Ph3 DataCLINICAL

AMGNH2 2026

Data from Supabase · Updated 2026-03-24